The relationship between patient-reported tolerability issues with oral antidiabetic agents and work productivity among patients having type 2 diabetes

Journal of Occupational and Environmental Medicine

Volumn 53, Issue 2, 2011, Pages 204-210

  DiBonaventura, Marco ^a   Link, Charles ^b   Pollack, Michael F ^c   Wagner, Jan Samuel ^a   Williams, Setareh A ^c  

^a KANTAR HEALTH   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT;

ABSENTEEISM; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALZHEIMER DISEASE; ANXIETY; ARTICLE; BIPOLAR DISORDER; CHRONIC BRONCHITIS; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CONSTIPATION; DEMENTIA; DEPRESSION; DIARRHEA; DISEASE DURATION; DRUG TOLERABILITY; EDUCATIONAL STATUS; EMPHYSEMA; ETHNICITY; FEMALE; HEADACHE; HEART INFARCTION; HEMIPLEGIA; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOGLYCEMIA; INCOME; KIDNEY FAILURE; LEUKEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRODUCTIVITY; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; TUMOR; ULCERATIVE COLITIS; WATER RETENTION; WEIGHT GAIN;

EID: 79952184933     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e318209e0ce     Document Type: Article

References (22)

1. American Diabetes Association. Standards ofmedical care in diabetes - 2009. Diab Care. 2009;32(suppl1):S13-S61.
2. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-732.
3. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 1994;11:223-241. (Pubitemid 24308246)
4. Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA. Association between oral antidiabetic use, adverse events, and outcomes in patients with type 2 diabetes. Diab Obes Metab. 2008;10:638-645. (Pubitemid 352044293)
5. Joy SV. Clinical pearls and strategies to optimize patient outcomes. Diabetes Educ. 2008;34(suppl 3):54S-59S.
6. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65:385-411. (Pubitemid 40227460)
7. Peyrot M, Rubin RR, Lauritzen T, et al; for the International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diab Care. 2005;28:2673-2679. (Pubitemid 43951158)
8. Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Paluschinat CA. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Drugs Aging. 2008;25:611-622. (Pubitemid 351918802)
9. Asche CV, McAdam-Marx C, Share-McWhorter L, Plauschinat CA. Evaluation of diabetes treatment patterns and adverse events in a usual care setting. Poster presented at American Society of Health-System Pharmacists 41st Mid-Year Meeting; December 2006; Anaheim, CA.
10. Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diab Res Clin Pract. 2010;87:204-210.
11. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410-1418.
12. Zarowitz BJ, Conner C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. Pharmacotherapy. 2009;29(pt 2):55S-67S.
13. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting US employers. J Occup Environ Med. 2004;46:398-412. (Pubitemid 38469017)
14. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diab Care. 2008;31:596-615.
15. Deleted in proof.
16. Brod M, Skovlund SE, Wittrup-Jensen KU. Measuring the impact of diabetes through patient report of treatment satisfaction, productivity, and symptom experience. Qual Life Res. 2006;15:481-491.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383. (Pubitemid 17055592)
18. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74. (Pubitemid 16125389)
19. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a Work Productivity and Activity Impairment instrument. Pharmacoeconomics. 1993;4:353-365.
20. Rodbard HW, Fox KM, Grandy S; Shield Study Group. Impact of obesity on work productivity and role disability in individuals with and at risk for diabetes mellitus. Am J Health Promot. 2009;23:353-360.
21. US Bureau of Labor Statistics. Highlights of Women's Earnings in 2008. Report 1017. Washington, DC: US Department of Labor; 2009. http/www.bls.gov/cps/ cpswom2008.pdf. Accessed October 5, 2009.
22. Bolge SC, Doan JF, Kannan H, Bara RW. Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res. 2009;18:415-422.